Treatment of Dementias

A New Generation of Progress

  • Edwin M. Meyer
  • James W. Simpkins
  • Jyunji Yamamoto
  • Fulton T. Crews

Part of the Advances in Behavioral Biology book series (ABBI, volume 40)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Cholinergic Drugs in Alzheimer’s Treatment

  3. Growth Factors in Alzheimer’s Treatment

    1. Front Matter
      Pages 97-98
    2. Paul A. Lapchak, Dalia M. Araujo, Millicent M. Dugich-Djordjevic, Franz Hefti
      Pages 99-111
    3. Kathleen T. Shiverick, Mohan K. Raizada, John A. Olson Jr.
      Pages 123-133
    4. Louis B. Hersh, Chuang Kong Fong, Yi-Ping Li, Craig Sampson, Gabriele Mues, Dana Hilt et al.
      Pages 135-144
    5. Tatsuo Mima, Kintomo Takakura, Shoei Furukawa, Yoshihide Hashimoto, Gunshiro Kato, Yasundo Yamasaki et al.
      Pages 157-169
    6. Millicent M. Dugich-Djordjevic, Paul A. Lapchak, Franz Hefti
      Pages 171-183
  4. Phospholipids in Alzheimer’s Treatment

    1. Front Matter
      Pages 185-185
    2. Maria Grazia Nunzi, Gino Toffano
      Pages 199-205
    3. Thomas H. Crook III, J. Tinklenberg, J. Yesavage, W. Petrie, C. Wells, M. G. Nunzi et al.
      Pages 207-224
  5. Ion Channel Modulators in Alzheimer’s Disease

    1. Front Matter
      Pages 225-225
    2. John F. Disterhoft, Richard A. Deyo, Lucien T. Thompson
      Pages 227-240
    3. L. T. Thompson, J. R. Moyer Jr., J. Black, J. F. Disterhoft
      Pages 241-256
    4. Rueben A. Gonzales, Laurie M. Brown, Timothy Schallert, Melanie S. Weaver, Khalid M. Shumburo
      Pages 257-275
  6. CNS Targeted Drug Delivery

    1. Front Matter
      Pages 299-300
    2. Marcus E. Brewster, Wesley R. Anderson, Nicholas Bodor
      Pages 301-316
    3. Edwin M. Meyer, Corinne R. Pruysers, Christopher M. de Fiebre, Sean Olof Bryant
      Pages 345-355
  7. Normal Aging

    1. Front Matter
      Pages 357-358
    2. J. A. Joseph, E. R. Mesco, K. Yamagami, M. Anson, R. Cutler
      Pages 359-375
    3. Pawels Kurian, L. Judson Chandler, Mark Gerber, Michael McKinney, Jacquelline H. Miller, Fulton T. Crews
      Pages 377-386
    4. J. G. Joshi, M. Clauberg, M. S. Dhar
      Pages 387-396
    5. Michael J. Meldrum, Patricia Moran, Ralph Dawson Jr.
      Pages 407-425
    6. Collin R. Park, Sabine M. von Preyss-Friedman, Robert S. Schwartz, Stephen C. Woods
      Pages 451-459
  8. Animal Models for Alzheimer’s Disease

    1. Front Matter
      Pages 461-462
    2. Jan Krzysztof Blusztajn, Amy Venturini, Henry J. Lee, Bruce H. Wainer
      Pages 463-469
    3. M. Catherine Bennett, David M. Diamond, W. Davis Parker, Stacy L. Stryker, Gregory M. Rose
      Pages 485-501
    4. Sandip Vyas, Xiaohong Zhao, T. Joakim Luick, Lawrence K. Duffy
      Pages 503-513
    5. Masatoshi Takeda, Tsuyoshi Nishimura, Takashi Kudo, Satoshi Tanimukai, Toshihisa Tanaka, Masayasu Okochi et al.
      Pages 515-526
  9. Back Matter
    Pages 527-533

About this book


Alzheimer's disease is one the foremost health problems facing every society fortunate enough to attain a level of medical care that ensures an average lifespan of over 70 years of age. The cause of the disease remains unknown, and no single therapeutic approach has yet been found highly efficacious. Indeed, as the complexity of its effects on brain neuronal systems becomes elucidated, the concept emerges that Alzheimer's disease may be an umbrella term for multiple Alzheimer's-type syndromes that can be differentiated based on etiology (hereditary versus sporadic), neurochemical deficits, and extent of pathology. Whether one or more disease processes is involved, it seems increasingly unlikely that any single drug will provide efficacious relief across the broad spectrum of symptoms reflected in large subject populations. Rational therapeutic approaches may yield long term amelioration of many symptoms in selected groups of patients; and individual symptoms may be ameliorated in larger populations. Multiple approaches may be combined to optimize therapeutic effects. For example, a variety of approaches remain focused on restoration of cholinergic neurodegeneration and enhancing cholinergic neurotransmission, whereas other approaches attempt to retard the of the brain that occurs during Alzheimer's disease. Chapters cover continuous degeneration topics from growth factor secretion of proteases, which could modify amyloid processing, to neuronal gene delivery using viral vectors. The breadth and thoroughness of the chapters truly embrace a broad spectrurn of models, pathological mechanisms and therapeutic approaches.


Alzheimer CNS Nervous System Syndrom alzheimer's disease brain central nervous system dementia dopamine drug drug delivery lipide oxidative stress stress syndromes

Editors and affiliations

  • Edwin M. Meyer
    • 1
  • James W. Simpkins
    • 1
  • Jyunji Yamamoto
    • 2
  • Fulton T. Crews
    • 1
  1. 1.University of FloridaGainesvilleUSA
  2. 2.Taiho Pharmaceutical CompanyTokushimaJapan

Bibliographic information

  • DOI
  • Copyright Information Plenum Press, New York 1992
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-6518-1
  • Online ISBN 978-1-4615-3432-7
  • Series Print ISSN 0099-6246
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Consumer Packaged Goods